Jackie Papkoff
Geen lopende functies
Profiel
Jackie Papkoff served as Chief Scientific Officer at CFD Therapeutics, Inc., Senior VP & Chief Scientific Officer-Microbiome at Assembly Biosciences, Inc., Senior Vice President-Research at Evelo Biosciences, Inc., and Vice President-Immunology Scientific Innovation at California Innovation Center.
Papkoff holds a doctorate degree from The Salk Institute for Biological Studies and the University of California San Diego, and an undergraduate degree from the University of California, Santa Cruz.
Eerdere bekende functies van Jackie Papkoff
Bedrijven | Functie | Einde |
---|---|---|
California Innovation Center | Corporate Officer/Principal | - |
ASSEMBLY BIOSCIENCES, INC. | Corporate Officer/Principal | - |
EVELO BIOSCIENCES, INC. | Hoofd Techniek/Wetenschap/O&O | - |
CFD Therapeutics, Inc.
CFD Therapeutics, Inc. Medical SpecialtiesHealth Technology CFD Therapeutics, Inc. (CFD), is being created to develop novel cancer therapeutics stemming from discoveries made previously by diaDexus. CFD will specifically focus on the development of therapeutic monoclonal antibodies directed against proprietary ovarian, pancreatic, breast, colon, prostate and lung cancer targets licensed from diaDexus. diaDexus, Inc. and San Francisco-based Biotechnology Value Fund L.P | Hoofd Techniek/Wetenschap/O&O | - |
Opleiding van Jackie Papkoff
The Salk Institute for Biological Studies | Doctorate Degree |
University of California San Diego | Doctorate Degree |
University of California, Santa Cruz | Undergraduate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Verwante bedrijven
Beursgenoteerde bedrijven | 2 |
---|---|
ASSEMBLY BIOSCIENCES, INC. | Health Technology |
EVELO BIOSCIENCES, INC. | Health Technology |
Bedrijven in privébezit | 2 |
---|---|
CFD Therapeutics, Inc.
CFD Therapeutics, Inc. Medical SpecialtiesHealth Technology CFD Therapeutics, Inc. (CFD), is being created to develop novel cancer therapeutics stemming from discoveries made previously by diaDexus. CFD will specifically focus on the development of therapeutic monoclonal antibodies directed against proprietary ovarian, pancreatic, breast, colon, prostate and lung cancer targets licensed from diaDexus. diaDexus, Inc. and San Francisco-based Biotechnology Value Fund L.P | Health Technology |
California Innovation Center |